Related Experiment Video

Updated: Jun 5, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Beta blockers in coronary artery disease with and without hypertension

Santanu Guha1, Saumitra Ray

  • 1Department of Cardiology, Medical College, Kolkata-700 019, West Bengal, India. guhas55@hotmail.com

Indian Heart Journal
|December 25, 2010
PubMed

Insights

Beta-adrenergic blockers (BB) are effective treatments for angina and myocardial infarction (MI). These drugs also offer benefits in heart failure and surgery recovery, and are preferred for hypertension in coronary artery disease.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-adrenergic blockers (BB) were initially developed for angina treatment.
  • Early trials demonstrated BB efficacy in myocardial infarction (MI) settings.
  • BB have shown long-term benefits in post-thrombolytic MI.

Purpose of the Study:

  • To review the established and debated roles of beta-adrenergic blockers (BB) in cardiovascular medicine.
  • To highlight BB efficacy in various cardiac conditions and surgical settings.
  • To address the current debate surrounding BB use in hypertension, particularly in patients with coronary artery disease.

Main Methods:

  • Literature review of clinical trials and evidence regarding beta-adrenergic blockers.
  • Analysis of BB effects on angina, myocardial infarction, congestive cardiac failure, and surgical outcomes.
  • Examination of the role of BB in hypertension management, especially in the context of coronary artery disease.

Main Results:

  • BB provide symptomatic relief in stable angina by reducing myocardial oxygen demand.
  • In unstable angina/non-ST elevation MI, BB prevent arrhythmia and progression.
  • BB are first-line treatments for congestive cardiac failure (CCF) and improve surgical outcomes.
  • BB have shown potential in retarding atherosclerosis progression.
  • While debated in general hypertension, BB remain preferred for hypertension in coronary artery disease.

Conclusions:

  • Beta-adrenergic blockers (BB) possess a wide range of established cardiovascular benefits.
  • Their role in managing angina, MI, CCF, and surgical recovery is well-supported.
  • Despite ongoing debate in hypertension, BB are the preferred choice for hypertensive patients with coronary artery disease.

Related Concept Videos

Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...